false
Catalog
Best Practice Case Studies
Hodgkin Lymphoma
Hodgkin Lymphoma
Back to course
Pdf Summary
This review provides a comprehensive overview of Hodgkin Lymphoma (HL), discussing its pathogenesis, diagnosis, and treatment approaches for adult patients. HL is a rare lymphoma, primarily affecting young adults, with a secondary incidence peak in individuals over 60. Historically, HL treatment has greatly advanced, shifting from an incurable condition to one with an excellent prognosis; first-line treatments, which combine chemotherapy and/or radiotherapy, yield an 80% cure rate.<br /><br />HL treatment varies by stage and risk factors. Early favorable-stage HL typically requires two cycles of ABVD chemotherapy and radiotherapy. For early-stage unfavorable HL, four cycles of ABVD, possibly followed by radiation, are common, although more intense eBEACOPP chemotherapy may be used in some cases. Advanced-stage HL often necessitates more rigorous treatment; eBEACOPP is standard, though ABVD remains widespread due to its less intensive nature.<br /><br />Treatment strategies for relapsed or refractory HL typically involve a second line of salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant (ASCT). Recent treatments include Brentuximab Vedotin and checkpoint inhibitors like nivolumab and pembrolizumab, which have shown significant promise in clinical trials, especially in cases refractory to standard therapies.<br /><br />In terms of epidemiology, HL occurs in 2–3 individuals per 100,000 per year, with genetic factors, Epstein-Barr Virus, and HIV infection as notable risk aspects. Diagnosis and staging rely on various imaging techniques and histopathological analysis.<br /><br />Future approaches aim to incorporate less toxic, targeted treatments like novel immunotherapies earlier in treatment courses, potentially improving efficacy and minimizing long-term side effects. Research emphasis also includes optimizing treatment regimens for older populations, who often experience more aggressive disease forms and less favorable outcomes.
Meta Tag
Edition
3rd Edition
Related Case
3rd Edition, CASE 42
Topic
Oncology
Keywords
3rd Edition, CASE 42
3rd Edition
Oncology
Hodgkin Lymphoma
pathogenesis
diagnosis
treatment
chemotherapy
radiotherapy
ABVD
eBEACOPP
Brentuximab Vedotin
checkpoint inhibitors
×
Please select your language
1
English